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Abstract
Most of current strategies for antiviral therapeutics target the virus specifically and directly, but an alternative approach to
drug discovery might be to enhance the immune response to a broad range of viruses. Based on clinical observation in
humans and successful genetic strategies in experimental models, we reasoned that an improved interferon (IFN) signaling
system might better protect against viral infection. Here we aimed to identify small molecular weight compounds that
might mimic this beneficial effect and improve antiviral defense. Accordingly, we developed a cell-based high-throughput
screening (HTS) assay to identify small molecules that enhance the IFN signaling pathway components. The assay is based
on a phenotypic screen for increased IFN-stimulated response element (ISRE) activity in a fully automated and robust format
(Z9.0.7). Application of this assay system to a library of 2240 compounds (including 2160 already approved or approvable
drugs) led to the identification of 64 compounds with significant ISRE activity. From these, we chose the anthracycline
antibiotic, idarubicin, for further validation and mechanism based on activity in the sub-mM range. We found that idarubicin
action to increase ISRE activity was manifest by other members of this drug class and was independent of cytotoxic or
topoisomerase inhibitory effects as well as endogenous IFN signaling or production. We also observed that this compound
conferred a consequent increase in IFN-stimulated gene (ISG) expression and a significant antiviral effect using a similar
dose-range in a cell-culture system inoculated with encephalomyocarditis virus (EMCV). The antiviral effect was also found
at compound concentrations below the ones observed for cytotoxicity. Taken together, our results provide proof of concept
for using activators of components of the IFN signaling pathway to improve IFN efficacy and antiviral immune defense as
well as a validated HTS approach to identify small molecules that might achieve this therapeutic benefit.
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Introduction
There has been significant progress in the development of
vaccines and therapeutics against viruses, but there are still major
gaps in medical therapy for some of the most common types of
viral infections. For these types of infections, vaccines can still be
ineffective due to new and emergent strains and can exhibit
significant off-target effects [1,2]. Similarly, the efficacy of antiviral
therapeutics can often be limited by pathogen resistance as
another sign of the difficulty in keeping up with rapidly evolving
viral genomes [3–9]. An alternative to agents that specifically and
directly target the virus itself is the possibility of improving natural
host defense against a broad range of viruses. Although antiviral
defense exhibits significant complexity and redundancy, one
system that stands out as a useful target for improvement is the
one based on the action of interferons (IFNs). And within this IFN
system, which is similarly complex, the STAT1 transcription factor
is remarkable as a central component that is critical for the
functional activity of each type of IFN (Figure 1). Consequently,
genetic loss of STAT1 function causes a marked susceptibility to
viral infection in mice and humans [10–12]. Moreover, modifi-
cation of STAT1 to a form) that improves the efficiency of IFN
signal transduction can result in improved control of viral infection
[13]. These observations indicate that the IFN-signaling pathway
is subject to a so-called ‘‘rheo-STAT’’ adjustment wherein down-
regulation causes increased susceptibility to viral infection whereas
up-regulation might lead to increased efficiencies for IFN-
stimulated gene (ISG) expression and control of infection [14].
In the present study, we aimed to mimic the beneficial actions of
STAT1 modification with a small molecule that also enhances the
activity of the IFN signaling pathway. We describe here the
development of a high-throughput screening (HTS) system for
novel small molecular weight compounds (so-called ‘‘small
molecules’’) that might increase ISG expression and antiviral
activity. To develop this screening system, we generated cell lines
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36594that stably express the human interferon-stimulated response
element (ISRE) driving a luciferase reporter gene. The ISRE gene
promoter element is responsible for type I IFN signaling that
mediates host defense against a wide range of viruses [15,16]. After
establishing that the ISRE-reporter cell line responded linearly to
IFN-b concentration and treatment time, we converted the assay
to an automated format for a screen against already approved or
approvable drugs. We also screened a library of phosphatase
inhibitors that might mediate increased STAT1 phosphorylation-
activation. Our analysis identified a series of diverse compounds
capable of significantly increasing ISRE activity. One compound
in particular, the anthracycline antibiotic idarubicin hydrochlo-
ride, was used to explore mechanism of action and to validate the
proposal that small molecules can enhance ISRE activity to drive
higher levels of ISG expression and improved control of viral level.
The findings provide for the concept that current antiviral
therapeutics act directly and specifically on viral proteins whereas
next-generation antivirals might act to enhance host immunity
against a broad range of viruses. Either alone or together, these
approaches might better address the current need for more
effective treatment against common as well as new and emergent
viral infections.
Results
Generation of a cell-based assay system for ISRE activity
Based on the observation that STAT1-CC-expressing cells show
increased activity of the endogenous ISRE promoter element [13],
we established cell lines that stably expressed an ISRE-containing
gene promoter driving a click beetle luciferase reporter gene
CBG99luc (Figure 2A). We used 2fTGH cells (the parental line for
STAT1-deficient U3A cells) as well as HEK293T cells that both
express endogenous STAT1. Clonal lines showing IFN-b-induc-
ible ISRE-promoter driven luciferase activity were designated
2fTGH- or HEK293T-ISRE-CBG99 cells. For initial assay
development, we used the 2fTGH- and HEK293T-ISRE-
CBG99 cells to establish an optimal luciferase light reaction time
for both cell-lines. Based on luminescence signal stability over the
time course of the reaction, an optimal readout window of 40–70
min after the start of the reaction was chosen for subsequent
experiments (Figure 2B). After optimization of cell growth time,
response to various IFN-b treatment times and concentrations
were tested in 2fTGH and HEK293T cell lines. Each cell line
exhibited a distinct IFN-b treatment time for maximal signal: 7–
12 h for 2fTGH-ISRE-CBG99 cells and 14–24 h for HEK293T-
ISRE-CBG99 cells. Although a lower signal magnitude was
obtained with 2fTGH-ISRE-CBG99 cells compared to
HEK293T-ISRE-CBG99 cells, the 2fTGH-ISRE-CBG99 cells
show more specificity for IFN-b (compared to IFN-c) treatment at
all IFN-b treatment time periods tested (Figure 2E) and over a
range of IFN-b (and IFN-c) concentrations (Figure 2F, G). Thus,
the 2fTGH-ISRE-CBG99 cells were chosen for further assay
development.
Assay automation and miniaturization
To achieve assay automation and miniaturization, the ISRE
activity assay was first automated in 96-well plates and then
reformatted for 384-well plates. In the 384-well format, the assay
exhibited a near-maximal signal at 8000 cells per well and
consistent well-to-well and plate-to-plate reproducibility (Fig-
ure S1). In 96- and 384-well formats, signal to background (S/B)
ratios, coefficients of variance, and Z9-factors achieved excellent
performance in comparison to published standards [17,18].
Representative results for 2fTGH-ISRE-CBG99 cells treated with
IFN-b (1000 U/ml) for 7 h compared to 1% DMSO vehicle alone
are provided in Table 1. The results indicate the development of a
quantitative and specific cell-based HTS assay of IFN-responsive
gene promoter activity.
Cell-based HTS of a small-molecule library
We used the automated ISRE-activity assay to perform a screen
of a 2240 chemical compound library. This library consisted of
2160 compounds from the Johns Hopkins Clinical Compound
Library (JHCCL) of FDA approved or approvable drugs [19,20].
In addition, we included 33 compounds from the Screen-Well
Phosphatase Inhibitor Library based on the observation that the
improvement in IFN signaling in STAT1-CC-expressing cells
correlated with prolonged phosphorylation of STAT1 and STAT2
[13]. Each compound was tested at 4 different concentrations
(0.24, 1.2, 6 and 30 mM) and simultaneous treatment with IFN-b
at 5 U/ml, the concentration at the initial inflexion of the IFN
concentration-response curve (as shown in Figure 2F). These
treatment conditions were duplicated on a second plate. Each
assay plate also contained control wells containing a range of IFN-
Figure 1. Scheme for IFN signal transduction. Type I IFN signaling starts by activation of the IFN-a/b receptor (IFNAR) and subsequent activation
of the IFNAR1-associated TYK2 and IFNAR2-associated JAK1, with consequent recruitment of STAT2. Phosphorylation of STAT2 enables reruitment of
STAT1 and release of the phosphorylated STAT1-STAT2 heterodimer bound to IRF-9. This complex binds to the IFN stimulated response element
(ISRE) and in concert with recruited transcriptional co-activators such as p300/CBP then drives IFN-stimulated gene (ISG) transcription.
doi:10.1371/journal.pone.0036594.g001
Screening for Interferon Signal Enhancers
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36594b concentrations (0–200 U/ml) in quadruplicate (Figure 3A). This
arrangement achieved excellent signal reproducibility between
duplicate compound plates as well as signal consistency through
the full screening run of 56 assay plates (28 duplicate pairs)
(Figure 3B, C).
After raw data were normalized, scaled to z-scores, and
summarized, we found that 321 data points (out of a total of
8960 data points representing the 2240 compounds tested at 4
concentrations) had an ISRE activity z-score $2 (Figure 4A). This
data set represented 285 individual compounds, as some
compounds had an ISRE activity z-score $2 at more than one
dose. Of these 285 compounds, 64 hit compounds (2.9% of the
total compound library) were selected for validation based on a
combination of dose-response characteristics and inter-replicate
reproducibility. This approach captured all 20 of the compounds
with the highest z-scores. In support of re-purposing as a drug
Figure 2. IFN responsivness of the ISRE-promoter luciferase-reporter system. (A) Schematic representation of the vector construct (ISRE-
CBG99) used to establish stable cell lines for monitoring ISRE activity driving a click beetle luciferase (CBL) reporter gene. (B) 2fTGH cells stably
expressing the ISRE-CBG99 construct (2fTGH-ISRE-CBG99 cells) were treated with IFN-b (1000 U/ml for 0–14 h) and then monitored for luciferase-
catalyzed luminescence over 0–4 h. Signal maximum was found at 50 min, and the optimal measurement window (OMW) with at least 90%
preservation of signal) was found at 40–70 min. (C) Time course for effect of IFN-b (1000 U/ml) and IFN-c (100 U/ml) on ISRE activity in 2fTGH-ISRE-
CBG99 cells. (D) Corresponding time course for HEK293T-ISRE-CBG99 cells. (E) Ratio of ISRE activities when each cell line is treated with saturating
concentrations of IFN-b versus IFN-c for 0–24 h. * indicates significant differences between values for 2fTGH versus HEK293T cell lines. (F)
Concentration-response curves for effect of IFN-b and IFN-c on ISRE activity in 2fTGH-ISRE-CBG99 cells. (G) Corresponding concentration-response for
HEK293T-ISRE-CBG99 cells.
doi:10.1371/journal.pone.0036594.g002
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range of drug classes (Figure 4B).
Screening hit idarubicin increases ISRE activity
independent of IFN
Each of the 64 primary hits was subjected to primary validation
for ISRE activity over a broader range of concentrations of drug
and IFN-b (0–15 U/ml). Among the primary and confirmed
screening hits, idarubicin hydrochloride ranked highest in potency
for enhancing ISRE activity (i.e., idarubicin exhibited a significant
effect at a lower concentration than other compounds). During the
ISRE validation, we found that idarubicin caused a concentration-
dependent increase in ISRE activity over a range of IFN-b
treatment concentrations, with highly significant effects as low as
25 nM idarubicin in combination with 15 U/ml IFN-b
(Figure 5A).
The structure for idarubicin shows characteristic features of an
anthracycline antibiotic unrelated to any other antiviral com-
pound in clinical use. To further validate the effect of idarubicin
on ISRE activity, we tested three other anthracyclines (daunoru-
bicin, doxorubicin, epirubicin) with very similar chemical struc-
tures to idarubicin. Each of these compounds also showed a
capacity to significantly increase ISRE activity (Figure 5B). In
addition, we found that the immune activators DMXAA
(Vadimezan) and Imiquimod did not cause any increase in ISRE
activity in the same concentration range (Figure 5C). These
compounds appear to directly activate immune cells (including
increased IFN production) [21,22]. However, for the present work,
we specifically studied non-hematopoietic cells since that popula-
tion appears critical for STAT1-mediated defense against at least
some types of viruses [11].
Table 1. Well-to-well reproducibility of automated ISRE
activity assay for 2fTGH-ISRE-CBG99 cells treated with IFN-b
(1000 U/ml for 7 h) versus DMSO vehicle alone.
Format S/B CV (%) Z9-factor
96 well 206 5.1 0.84
384 well 112 10.9 0.70
Abbreviations: S/B, signal to background ratio; CV, coefficient of variation.
doi:10.1371/journal.pone.0036594.t001
Figure 3. Reproducible and stable signals from HTS of the chemical library. (A) Schematic of assay plate map used in screening the
chemical compound library. (B) Reproducibility of raw data between duplicate assay plates for control wells containing IFN-b (0–200 U/ml) and test
wells containing compound plus IFN-b (5 U/ml). Dashed lines indicate median 6 SD of each data set from the test wells. (C) Signal consistency
through a full screen of 56 assay plates. Values represent replicate A of assay plate 1 (the first plate) and plate 55 (the last plate). Box plots represent
median and 25
th and 75
th percentile, and whiskers indicate minimum and maximum of data. Arrows indicate values from test wells.
doi:10.1371/journal.pone.0036594.g003
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with previous observations [23,24]. Under the present conditions,
the major effect of idarubicin on cell viability was detected at drug
concentrations .3 mM, so that the ISRE-activating effect of
idarubicin occurred at concentrations below those that cause a
major effect on cell viability (Figure 5D). Nonetheless, idarubicin is
best known as an anti-neoplastic agent that acts via DNA
intercalation and topoisomerase II inhibition [25]. To determine
whether the effect of idarubicin on ISRE activity is related to
topoisomerase II inhibition, we tested three other potent
topoisomerase inhibitors Etoposide, Hu-0331, and ICRF-193 up
to concentrations known to cause topoisomerase II inhibition [26–
28]. In contrast to idarubicin, these other compounds caused no
significant increase in ISRE activity (Figure 5E). In fact, two of the
topoisomerase inhibitors (Etoposide and Hu-0331) caused a
decrease in ISRE activity in concert with cytotoxic effects at
higher concentrations. These findings indicate that the capacity of
idarubicin to activate the ISRE component of the IFN signaling
pathway occurs independently of topoisomerase inhibition.
Together, the findings provide evidence of idarubicin capacity to
increase ISRE activity independent of the anti-neoplastic proper-
ties of the drug.
Figure 4. Hit selection and therapeutic class of drugs from primary HTS assay for ISRE activation. (A) Plot of z-scores for each of the 2240
compounds subjected to the primary screen for ISRE activation. Values represent mean of two replicates per compound concentration. Compounds
are ranked by highest z-score achieved at any of the four compound concentrations tested. Dashed lines demarcate the compounds with z-scores
greater than 2 SD above the mean; and red color denotes the 64 hit compounds selected from this group for validation. (B) The distribution of the 64
hit compounds into various therapeutic classes. Values indicate the number of compounds in each class.
doi:10.1371/journal.pone.0036594.g004
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anthracyclinesonISREactivityoccurredatalowerconcentrationof
drug when IFN-b was co-administered, particularly at the highest
concentration of IFN-b (15 U/ml) (Figure 5A). For example, the
EC50 for idarubicin decreased as the concentration of IFN-b
increased (Table 2). These findings suggested that idarubicin might
somehow interact with the IFN signaling pathway. In that regard,
we also found that the effect of idarubicin on ISRE activity was
observed under baseline conditions when there was no detectable
production of endogenous IFN-b and no administration of
exogenous IFN-b (data not shown and Figure 5A). These results
suggested that the effect of idarubicin on ISRE activity is
independent of IFN production or action. Indeed, we also found
that the effect of idarubicin on ISRE activity persisted without
change during effective IFN-a/b receptor 2 (IFNAR2) blockade
(Figure 6). Together, the findings indicate that idarubicin causes an
Figure 5. Validation and specifcity of idarubicin capacity for ISRE activation. (A) Idarubicin concentration-response for ISRE activity without
and with treatment with IFN-b (1, 5, and 15 U/ml). 2fTGH-ISRE-CBG99 cells were treated with idarubicin and IFN-b for 8 h. Overall significance for
idarubicin dose P,0.0001, IFN-b dose p,0.0001, and Interaction p,0.0001. The p-values for individual comparisons (versus control without
idarubicin) are from Bonferroni post-tests from two-way ANOVA (idarubicin x IFN dose). Symbols: * p,0.05, ** p,0.01, *** p,0.001. (B)
Corresponding data for daunorubicin, doxorubicin, and epirubicin concentration-response for ISRE activity. (C) Corresponding data for DMXAA and
Imiquimod concentration-response for ISRE activity. Overall significance for compound dose p=ns, IFN-b dose p,0.0001, interaction p=ns. (D)
Idarubicin toxicity determined using Alamar Blue metabolism assay. Cells were treated with drug for 12 h. (E) Etoposide, Hu-0331, and ICRF-193 (0–
100 mM) concentration-response for ISRE activity without and with IFN-b (1, 5, and15 U/ml). Overall significance for ICRF-193 dose p=ns, IFN-b dose
p,0.0001, interaction p=ns; for Etoposide and HU-0331 dose, there is a significant inhibitory effect on ISRE activity, p,0.0001, IFN-b dose p,0.0001,
interaction p,0.0001.
doi:10.1371/journal.pone.0036594.g005
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IFN-receptor interaction and instead acts downstream of ligand-
receptor binding in the IFN signaling pathway.
Idarubicin enhances IFN-driven ISG expression and
antiviral activity
We subjected idarubicin to further validation as an ISRE
activator in assays of ISG expression and antiviral activity. For
ISG expression, U3A (STAT1-null) and U3A-STAT1 cells were
treated with a range of concentrations of idarubicin and IFN-b
and then harvested for gene expression using quantitative real-
time PCR assay. We found that idarubicin increased the
expression of the antiviral gene 29,59-oligoadenylate synthetase 1
(OAS1), particularly with IFN-b treatment (Figure 7). There was no
effect of drug on ISG expression in STAT1-null U3A cells,
indicating that the drug is specific for STAT1-dependent gene
expression. We found similar results for the antiviral ISG
guanylate-binding protein 1 (GBP1) and three other ISGs (MX1,
PARP9, and IRF1) (Figure 6 and data not shown).
For antiviral activity, 2fTGH cells were treated with idarubicin
along with or without IFN-b and then assessed for control of
encephalomyocarditis virus (EMCV) levels and virus-induced
cytopathic effect. We selected EMCV since it was previously
found to be sensitive to STAT1-CC-dependent improvement in
IFN signaling [13]. In the present experiments, we found that
idarubicin treatment (at a relatively low concentration of 25 nM)
caused a significant decrease in EMCV titer at baseline and with
IFN-b treatment (at a relatively low concentration of 5 U/ml)
(Figure 8A). In addition, we observed that idarubicin-dependent
improvement in viral control translates into a significant decrease
in viral cytopathic effect under those same treatment conditions
(Figure 8B). Higher concentrations of idarubicin in combination
with IFN-b treatment caused a significant cytotoxic effect (data not
shown), consistent with the antineoplastic properties of the drug.
Nonetheless, the results with a relatively low concentration of
idarubicin provide proof-of-concept that a small molecule
activator of the ISRE component of the IFN signaling pathway
will allow for increased ISG expression and improved control of
viral level.
Discussion
The present study was undertaken to discover antiviral
therapeutics that broadly increase host defense. We focused on
the IFN system that is central to the antiviral response, although
we recognized that other labs have pursued this target with limited
success in the past. Some of these previous investigators have used
administration of IFN itself to increase the antiviral response, but
for this therapeutic goal and others, the side effects of IFN
administration have proven to be rate-limiting [29]. Similarly,
other investigators have attempted to boost IFN production, e.g.,
through administration Toll-like receptor (TLR) agonists CpG or
Imiquimod, but these agents have also caused similar side effects
[30–33]. The small molecule DMXAA activates multiple immune
pathways (NF-kB, TBK1/IRF3, NOD, and MAP kinase) but was
ineffective as an antiviral unless it was administered before
infection [34–37]. To circumvent at least some of these issues with
IFN production, toxicity, and specificity, we therefore pursued the
goal of antiviral drug discovery with a novel screening approach
Figure 6. Effect of IFN-receptor blockade on idarubicin stimulation of ISRE activity. Idarubicin concentration-response for ISRE activity
without and with treatment with IFN-b (1, 5, and15 U/ml) in the absence or presence of anti-IFNAR2 blocking mAb. *,{=p,0.05 ; **,{{=p,0.01;
***,{{{=p,0.001. p-values for individual comparisons are from Bonferroni post-tests from repeated measures two-way ANOVA, comparing the 0 nM
Idarubicin condition to the other drug doses. For 15 U/ml IFN-b, overall significance: anti-IFNARII, p,0.0001, IDA dose, p,0.0001; interaction,
p=0.0023. For 5 U/ml IFN-b, overall significance: anti-IFNARII, p,0.0001, IDA dose, p,0.0001; interaction, p=0.3294. For 1 U/ml IFN-b, overall
significance: anti-IFNARII, p,0.0892, IDA dose, p,0.0001; interaction, p=0.1542. For 0 U/ml IFN-b, overall significance: anti-IFNARII, p,0.4432, IDA
dose, p,0.0001; interaction, p=0.7677.
doi:10.1371/journal.pone.0036594.g006
Table 2. Idarubicin effect on ISRE activity relative to IFN-b
treatment concentration.
IFN-b (U/ml) EC50* Confidence Interval R
2
0 394.7 378.7–411.2 0.93
1 361.9 321.1–408.0 0.92
5 224.7 149.2–338.5 0.69
15 15.97 11.75–21.70 0.68
*Values for EC50 were calculated by fitting the data to a four-parameter
concentration-response curve for idarubicin effect on ISRE activity as described
in Methods.
doi:10.1371/journal.pone.0036594.t002
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boost the activity or efficiency of the IFN signaling pathway.
Our specific approach was based on previous success with the
use of a modified STAT1 signaling pathway. In this work, we
demonstrated that a designer form of STAT1 (designated STAT1-
CC based on double-cysteine substitutions) was able to enhance
IFN signaling and better control viral replication [13]. Although
STAT1-CC gene expression would be challenging to translate to
practical application, the mechanism of action served as a guide to
design a screening strategy to identify small molecules that could
mimic the antiviral benefit. In that regard, we also recognized that
phenotypic screening approaches have proven to be more effective
than target-based approaches for the discovery of first-in-class
small molecule drugs [38]. Thus, target-based approaches (defined
as direct drug action on a particular target) allow for analysis and
refinement of structure and function but can also waste resources
when the molecular hypotheses used to design screening assays
may not be relevant to the disease. Meanwhile, phenotypic
screening can take longer in terms of hit-to-lead development but
provide more proteins in the pathway to be targeted and do not
require prior knowledge of molecular mechanisms of action. Most
importantly, the activity found in phenotypic-based approaches is
often more effectively translated into therapeutic impact in disease
models. For the present work, we take advantage of both of these
strategies to some extent and devise a screen that incorporates
molecular mechanism (i.e., enhancing a specific type of IFN
signaling pathway) and the need to achieve phenotype (i.e.,
identifying any compound that could increase this type of signaling
pathway regardless of specific mechanism).
Considering these factors and observations in the STAT1-CC
model system, we designed a cell-based luciferase reporter assay
for measuring type I-dependent ISRE activity. This assay proved
to yield excellent signal-to-background and Z factors, specificity
for IFN-b treatment over IFN-c treatment, and suitability for
automation and screening. Furthermore, because the construct
design uses the Click Beetle Green luciferase, the assay can be
Figure 7. Idarubicin induces STAT1-dependent gene expression. U3A-STAT1 and U3A (STAT1-null) cells were treated with idarubicin for 1.5 h
followed by IFN-b for 12 h and then determination of OAS1 and GBP1 mRNA levels using real-time quantitative PCR assay. Overall significance for
idarubicin dose p,0.0001, IFN-b dose p,0.0001, and interaction p,0.0001. The p-values for individual comparisons (vs 0 idarubicin control) are from
Bonferroni post-tests from two-way ANOVA (idarubicin x IFN dose). Symbols: * p,0.01, ** p,0.001.
doi:10.1371/journal.pone.0036594.g007
Figure 8. Idarubicin provides control of viral titer. (A) 2fTGH cells were treated with idarubicin or DMSO vehicle and with IFN-b for 6 h and
then inoculated with EMCV (MOI 1) for 1 h. Viral titers in cell supernatant were measured at 28 h after inoculation using real-time quantitative PCR
assay for EMCV RNA. Values represent mean 6 SE (n=3 biological replicates, n=2 technical replicates). Overall significance for idarubicin dose
p,0.0001, IFN dose p,0.0001, and Interaction p,0.05. (B) For the protocol used in (A), the corresponding levels of virus-induced cell toxicity based
on cell viability from propidium iodide (PI) staining. Overall significance for idarubicin dose P,0.0001, IFN dose p,0.0001, and Interaction p=ns. The
p-values for individual comparisons (vs 0 idarubicin control) are from Bonferroni post-tests from two-way ANOVA (idarubicin x IFN dose). Symbols:
*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0036594.g008
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assays to report activity of other signaling pathways, including the
type II IFN-c activated sequence (GAS) promoter activity that
mediates defense against intracellular bacteria. A related approach
was used to screen for small molecules that increase GAS activity
for anti-proliferative and pro-apoptotic effects in cancer cells [39].
Others screened for compounds that inhibit Type I IFN
production and signaling [40]. An ISRE-RFP reporter system
has also been used to screen for assessing the effects of immuno-
stimulatory RNA [41]. Others have used a less directed approach
to screen for compounds that might use any mechanism to
decrease viral levels [40,42–45]. However, to our knowledge, the
present study conducts the first semi-quantitative screen measuring
ISRE activity to discover small molecule enhancers of the type I
IFN signaling pathway as broad-spectrum antiviral therapeutics.
Our primary screen identified idarubicin on the basis of its
capacity to significantly increase ISRE activity. Subsequent
validation assays demonstrated that idarubicin facilitates
STAT1-dependent ISG expression and STAT1-directed control
of viral replication and cytopathic effect. While others previously
reported the antiviral properties of anthracyclines some time ago,
no mechanism of their antiviral action was elucidated [46–48]. In
the present study, we observed drug-induced cytotoxicity in a
dose-range similar to those reported previously [23,24], however,
we establish that the effect of idarubicin on the antiviral IFN
pathway is independent of cytotoxicity and topoisomerase
inhibition. Because idarubicin enhances the IFN signaling
pathway output, we questioned whether the drug might also
cause IFN-driven cell death. However, we found no increase in
cytotoxicity in cells treated with idarubicin and IFN together
compared to cells treated with idarubicin alone. We also found
that the idarubicin concentrations for activating the ISRE
component of the IFN signaling pathway were significantly less
than those required for major cytotoxicity. Thus, we conclude that
idarubicin effect on IFN signaling is distinct from the effect on
DNA-based cytotoxicity. The dose dependency of these effects
underlines the need to conduct screening at multiple concentra-
tions of test compounds, particularly lower concentrations that
prevent false negative hits due to cytotoxic effects.
In a further analysis of drug mechanism, our study demonstrates
that the antiviral activity of idarubicin and other closely related
anthracyclines is derived from enhancing the activity of the type I
IFN signaling pathway. Our data further show that the enhancing
effect of idarubicin is based on ISRE activation and ISG
expression independent of IFN production or IFN–IFN-receptor
interaction, since the effect of idarubicin is unchanged by IFN-
receptor blockade. These findings suggest that idarubicin activa-
tion of the ISRE is due to an action in the IFN signaling pathway
distal to ligand-receptor binding, e.g., at the level of receptor-
associated JAK kinases or further downstream at the formation,
transport, binding, and/or assembly of the ISRE transcriptional
complex. In that regard, anthracyclines are known to inhibit DNA
and RNA synthesis by intercalating between base pairs of the
DNA/RNA strand to prevent replication, but whether this
mechanism can affect ISRE or other gene promoter elements still
needs to be defined. The present screening approach overcomes
the uncertainty in molecular mechanism by using a phenotypic
(rather than a target-based) screening approach and thereby
captures compounds that increase the activity of the IFN signaling
pathway by either established or undefined mechanisms.
In sum, we describe and validate a phenotypic screening
strategy to identify small molecules that enhance the activity of the
type I IFN signaling pathway and consequently improve antiviral
host defense. This approach is designed to lead to discovery of
drugs with activity against a broad range of viruses for clinical
application as well as experimental tool compounds to further
understand IFN-dependent immune mechanisms. Current ap-
proaches to defining the basis for IFN signal transduction,
particularly in vivo, often rely on complex transgenic and gene
targeting approaches. Thus, the use of small molecule enhancers
(SMEs) of the IFN signaling pathway may provide much greater
flexibility and ease of application to achieve transient adjustment
of IFN-related actions and consequent scientific and clinical
benefit. Our approach should thereby prove useful to discover
drugs with activity against a broad range of viruses as well as
effectiveness in other conditions (e.g., multiple sclerosis and
melanoma) where the efficacy of IFN treatment might benefit
from enhancing the IFN signaling pathway.
Materials and Methods
Stimulating agents and chemical compounds
IFN-b and IFN-c were obtained from PBL Interferon source
(Piscataway, NJ), diluted and aliquoted according of manufactur-
er’s recommendation, and stored at 280uC. The Johns Hopkins
Clinical Compound Library (JHCCL) was obtained from Dr.
David Sullivan at the Johns Hopkins University [19,20]. The
Screen-Well Phosphatase Inhibitor Library was obtained from
Enzo Life Sciences (Farmingdale, NY). All other chemical
compounds were obtained from Sigma Aldrich (St. Louis, MO).
Vector construction and stable transduction of cell lines
To construct the pISRE-CBG99 vector, we first generated a 5x-
repeat of the ISRE sequence and a TATAA box (5xISRE-
TATAA) in the pUCMinusMCS vector from Blue Heron
Biotechnology (Bothell, WA) and then cloned this sequence into
the Chroma-Luc pCBG99-Basic reporter vector from Promega
(Madison, WI) and ligated into Xma1 and Nco1 sites using T4
DNA ligase from Life Technologies (Carlsbad, CA). The DNA
sequence of the resultant pISRE-CBG99 vector was confirmed by
carrying out BigDye Terminator v3.1 sequencing reactions (Life
Technologies) on an ABI capillary sequencer. This vector and the
pPUR selection vector from Clontech (Mountain View, CA) were
co-transfected at a 9:1 ratio into 2fTGH or HEK293T cells to
increase the likelihood that cells tolerating puromycin selection
(0.5 mg/ml) contained one or more copies of pISRE-CBG99 in
addition to pPUR. The 2fTGH cells [49] were obtained from G.
Stark (Cleveland Clinic), and HEK293T cells [50,51] were
obtained from T. Brett (Washington University). Transfection
was performed using Fugene6 transfection reagent from Roche
Applied Science (Indianapolis, IN). Limiting dilution was used to
obtain individual cell clones that were then screened for luciferase-
mediated luminescence after treatment with IFN-b (1000 U/ml)
on a BioTek Synergy 4 multimode plate reader (BioTek,
Winooski, VT). Clonal cells exhibiting stable expression were
then used for further assay development.
Optimization and validation of ISRE activity-luciferase
reporter assay
To optimize the luciferase light reaction, we tested a series of
flash and glow luminescent substrate systems in both lysed and live
2fTGH-ISRE-CBG99 and HEK293T-ISRE-CBG99 cells, includ-
ing D-luciferin (Fisher Scientific, Pittsburgh, PA), the Chroma-Glo
Luciferase assay system from Promega and the steadylite plus
reporter gene assay system from Perkin Elmer (Waltham, MA)
under a range of incubation conditions. The steadylite plus system
was selected based on kinetic profile. Effects of IFN-b concentra-
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Assay automation
The assay was automated in a 96-well format with a customized
and fully integrated robotic system. The system equipment
included: a Caliper Sciclone ALH 3000 workstation (Perkin
Elmer) and a EL406 washer (BioTek) for liquid handling, an
automated Liconic incubator (Thermo Scientific) for cold storage
of plates, an automated Cytomat incubator (Thermo Scientific) for
cell culture environment, a separate hotel for storage of plates at
room temperature, a Synergy 4 plate reader, a Flexiseal plate heat
sealer (K Biosciences, Beverly, MA), a Caliper Twister II, and a
Beckman Sagian Orca robotic arm on a linear rail (Beckman
Coulter, Fullerton, CA). Construction allowed for transfer of
plates, reagents, and plasticware between all instruments, so that
there was no need for any manual interference during screening
assays. This entire system was enclosed in a custom-made laminar
flow hood to allow for HTS screening capability under BSL2
sterile conditions. After the system demonstrated satisfactory
performance in a 96-well format, the assay was miniaturized to
a 384-well format and re-tested for reproducibility and stability
under IFN-b and vehicle (1% DMSO) treatment conditions.
High-throughput screen
To achieve simultaneous treatment of cells with IFN-b and
various compound concentrations and to avoid reagent degrada-
tion over time, the screen was run in a modular manner with a
precise timeline (Figure S2). The first step included production of
plates with appropriate concentrations of compound and IFN-b
and then storage at 4uC. A separate plate was made for each of the
four compound concentrations (0.24, 1.2, 6 and 30 mM). The
Twister II, Sciclone, Orca, and Liconic cold storage incubator
handled this step. For the second step, cells were plated at
8000 cells per well in 384-well assay plates (n=56). This step was
accomplished in seven batches (8 assay plates per batch) using the
Sciclone. A uniform suspension of cells was maintained by
intermittent mixing on the Sciclone deck between cell plating.
Simultaneously, the compound stock plates were sealed using the
Flexiseal and stacked back into a Twister II rack for storage. For
the third step, cells were allowed to grow for 11 h and then were
treated with compound and IFN solutions. This step required that
a plate containing cells be brought from the Cytomat incubator to
the Sciclone deck in concert with a set of compound/IFN dilutions
plates from the cold storage incubator. Cell treatments were timed
so that each assay plate would be incubated for 10.3 h before the
final step of performing the luciferase assay. For this last step,
robotics were programmed so that each assay plate developed the
luciferase light reaction for 40 min at 25uC in the plate hotel and
then was delivered to the Synergy 4 plate reader for determination
of luminescence. For this assay, the BioTek EL406 washer was
used for aspiration of media and dispersion of substrate. In
entirety, the screen took 41.6 h to complete.
HTS data analysis
The raw data from the HTS assay were subjected to statistical
analysis using cellHTS2 [52,54], a software package designed for
the analysis of HTS data as part of the Bioconductor project for
statistical computing [55]. Raw data were normalized using the
plate median method [52,56]. Next, a z-score transformation was
applied to center and scale the data across the experiment.
Replicates for a given compound at a given dose (N=2 for each
dose/compound combination) were then mean summarized. A z-
score threshold of $2 was chosen to identify potential hits.
Thereafter, to reach a smaller and tractable set of hits to validate
experimentally, we took advantage of testing each compound at
four concentrations. Specifically, we used self-organizing maps
analysis to cluster hit compounds by shape of the dose-response
curve. The significance of change from dose to dose (0.24 to 1.2,
1.2 to 6, and 6 to 30) was also analyzed using linear models and
moderated F-statistics as implemented in the limma package [57]
in Bioconductor [55]. The concentration-response curves for each
compound were then visually inspected, using scatter plots
generated in TIBCO Spotfire DecisionSite (TIBCO, Palo Alto,
CA), with respect to the shape of the curve and reproducibility
between replicates. Compounds showing an erratic concentration-
response (e.g. increase, then decrease, and increase again in ISRE
activity with increasing concentration) were rejected. Compounds
with a consistent increase or decrease in response with increasing
drug concentration or good efficacy at any concentration were
included for further validation. This approach led to selection of
64 compounds for further validation, including compounds with
the 20 highest z-scores.
Hit validation, drug potency (EC50) estimation, and IFN
dependence
Hits from the primary screen were validated using the ISRE
activity-luciferase reporter assay over a broad range of compound
concentrations(0.01–25 mM)intheabsenceorpresenceofIFN-b(1,
5, and 15 U/ml). To determine drug potency, as defined by half-
maximal effective concentration (EC50), this data was fit to a four-
parameter concentration-response curve as described previously
[58] using the log agonist concentration versus response, variable
slope algorithm in GraphPad Prism 5 software (La Jolla, CA) where
Y=Bottom + (Top-Bottom)/(1+10 ˆ((LogEC50-X)*HillSlope)). To
determine whether compound effect depended on IFN production,
theISREactivity-luciferasereporterassaywasalsoperformedinthe
presenceofmouseanti-humanIFN-a/breceptorchain2(IFNAR2)
blocking mAb (clone MMHAE-2; Millipore, Billerica, MA) at a
concentration of 4 mg/ml.
Compound toxicity assay using Alamar Blue
A resazurin (Alamar Blue) metabolism assay was used to assess
cell toxicity during compound treatment [59]. For these experi-
ments, cells were treated with compound or an equivalent
concentration of vehicle (DMSO) for 12 h, and the medium was
replaced with fresh medium containing resazurin (80% dilution of
Tox-8 kit, Sigma-Aldrich, St. Louis, MO). After 1.5 h at 37uC
under standard culture conditions, the fluorescence of the resultant
product resorufin was measured using the Synergy 4 plate reader.
Wells with cells containing no compound (DMSO alone) and wells
containing no cells were used as 100% and 0% viability controls.
Data were normalized to calculate percentage viability.
Analysis of ISG expression
Expression of ISG’s was assessed with real-time quantitative
PCR assay for the corresponding mRNA level. For these
experiments, U3A and U3A-STAT1 cells were first treated with
the programmed combination of compound and IFN-b for 12 h
and then were washed twice with cold Dulbecco’s PBS followed by
lysis with Cells-to-cDNA II lysis buffer (Life Technologies) and
treatment with DNase according to the manufacturer’s instruc-
tions. The U3A cells were obtained from G. Stark (Cleveland
Clinic) and complemented with STAT1 to generate U3A-STAT1
cells as described previously [13]. A 25-ml aliquot of the cell lysate
was used to generate cDNA using the High Capacity Reverse
Transcription Kit (Life Technologies). The resulting cDNA was
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Technologies). Average cDNA concentration was 71625 ng/ml.
Subsequent PCR assays were performed in adherence with MIQE
guidelines [60,61], including the design of assays for ISGs (OAS1
and GBP1) and normalizer gene ornithine decarboxylase antizyme
(OAZ1). The normalizer gene OAZ1 was selected and validated for
cell samples treated with and without IFN-b. In brief, candidate
normalizer genes were selected from a combination of invariant
genes selected from previous microarray data [11,62,63] and prior
large-scale analyses of publicly available microarray data [64,65].
These candidates were then tested using real-time quantitative
PCR assays. Comparison of candidate normalizer gene expression
between various IFN treatment and infection conditions using
multiple software packages [66 68] led to the selection of the
OAZ1 as the normalizer gene. Primers and probes for real-time
quantitative PCR assays were designed using the ProbeFinder
design algorithm (Roche Applied Science). For OAS1, 59-
ggtggagttcgatgtgctg-39 and 59-aggtttatagccgccagtca-39 were used
as forward and reverse primers, along with UPL probe #37
(Roche Applied Science). A plasmid containing OAS1 transcript
variant 2 cDNA (Ref ID NM_002534, Origene, Rockville, MD)
was used as a standard for absolute quantitation of OAS1 copy
number. For GBP1, 59-ttccaaaactaaaactctttcagga-39 and 59-
tgctgatggcattgacgtag-39 were used as forward and reverse primers,
along with UPL probe #85. A plasmid containing the GBP1
cDNA (Clone ID: 3606865, Thermo Open Biosystems, Huntsville,
AL) was used as a standard. The IDT PrimeTime pre-designed
assay Hs.PT.42.328511.g (Integrated DNA Technologies, Coral-
ville, IA) was used for OAZ1. A cDNA vector was used for OAZ1
as well (Clone ID: LIFESEQ913650, Thermo Open Biosystems).
Data were collected on a LightCycler 480 instrument (Roche
Applied Science). Quantification cycle values were calculated
using a second derivative maxima algorithm as implemented in the
Lightcycler 480 software.
Viral inoculation and assessment of cell viability
Cells were cultured overnight and then treated with compound
and IFN-b for 6 h. Thereafter, cells were washed and then were
inoculated with EMCV (strain VR-129B, ATCC, Manassas, VA)
for 1 h at MOI 1 as described previously [13]. Cells were then
washed twice and cultured in medium containing 2% fetal bovine
serum for 28 h. At that time, cell supernatants were used to
determine viral titer based on real-time quantitative PCR assay for
EMCV RNA with 59-ctgccttcggtgtcgc-39 (forward primer), 59-
tgggtcgaatcaaagttggag-39 (reverse primer), and 59caaggtttt-
gagcgtgtctacgatgtgg-39 (probe). A TA plasmid containing the
EMCV 3D protein was used as a standard for absolute
quantitation of viral copy number. In addition, cell viability was
determined using the Cellomics Arrayscan VTi high content
imager (Thermo Scientific). For this assay, 15 images per well
were obtained with a 10x objective. After background subtraction,
cells were identified by nuclei stained by cell permeable dye
Hoechst 33342. Propidium iodide fluorescence was quantified by
defining a boundary of 2 pixels around the nuclei and then gating
on a cell population that showed higher staining. For each sample
replicate, cytotoxicity was calculated as the percentage of cells that
showed increased propidium iodide staining based on samples of
at least 5000 cells per well.
Supporting Information
Figure S1 Miniaturization and automation of the ISRE
activity assay. (A) Effect of cell density on ISRE activity as a
function fo IFN-b concentration in 384-well plates. B) Well-to-well
reproducibility for the assay performed in 384-well automated
format using 8000 cells per well.
(EPS)
Figure S2 Scheme for the HTS automation protocol.
Each box represents one of the sequential steps in the screening
process. Timing and time allotment for each step is also indicated.
(EPS)
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